Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.

MLA

Holdhof, Dörthe, et al. “Atypical Teratoid/Rhabdoid Tumors (ATRTs) with SMARCA4 Mutation Are Molecularly Distinct from SMARCB1-Deficient Cases.” Acta Neuropathologica, vol. 141, no. 2, Feb. 2021, pp. 291–301. EBSCOhost, https://doi.org/10.1007/s00401-020-02250-7.

APA

Holdhof, D., Johann, P. D., Spohn, M., Bockmayr, M., Safaei, S., Joshi, P., Masliah-Planchon, J., Ho, B., Andrianteranagna, M., Bourdeaut, F., Huang, A., Kool, M., Upadhyaya, S. A., Bendel, A. E., Indenbirken, D., Foulkes, W. D., Bush, J. W., Creytens, D., Kordes, U., … Schüller, U. (2021). Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 141(2), 291–301. https://doi.org/10.1007/s00401-020-02250-7

Chicago

Holdhof, Dörthe, Pascal D Johann, Michael Spohn, Michael Bockmayr, Sepehr Safaei, Piyush Joshi, Julien Masliah-Planchon, et al. 2021. “Atypical Teratoid/Rhabdoid Tumors (ATRTs) with SMARCA4 Mutation Are Molecularly Distinct from SMARCB1-Deficient Cases.” Acta Neuropathologica 141 (2): 291–301. doi:10.1007/s00401-020-02250-7.